Viking Scientific has developed a next-gen delivery technology that uses drugs as the backbone of an extended-release hydrogel polymer. We have received 'notice of allowance' from the USPTO on two patents to support our technology platform. Our first product is a Temozolomide hydrogel to treat Glioblastoma. Implanted directly at the tumor resection site, it uses a proven drug to overcome limitations such as Leukopenia and the blood-brain barrier.